---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-004562"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T02:55:32.161451+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Esperion appoints Eric Warren as Chief Commercial Officer; salary $444K, bonus target 35%

## Summary
- Eric Warren appointed CCO effective March 1, 2022; he was previously VP US Sales and Marketing since Jan 2021.
- Annual base salary $444,000; eligible for annual bonus targeted at 35% of base salary.
- Severance: 1x base salary plus target bonus if terminated within 12 months after a Sale Event.
- Outside Sale Event: severance of 9 months' base salary plus COBRA contribution.
- Warren has experience at Sanofi, Merck, and Nabriva Therapeutics.

## SEC filing metadata
- accession: 0001628280-22-004562
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828022004562/0001628280-22-004562-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828022004562/espr-20220301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-004562
- JSON: https://secwatch.observer/filing/0001628280-22-004562.json
- Plain text: https://secwatch.observer/filing/0001628280-22-004562.txt

## Key facts
- Executive change
  Eric Warren was appointed as Chief Commercial Officer at Esperion Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Commercial Officer
  source text: On March 1, 2022, the board of directors (the “Board”) of Esperion Therapeutics, Inc. (the “Company”) appointed Eric Warren, R.Ph. as the Company’s Chief Commercial Officer pursuant to the terms of an employment agreement with Mr. Warren (the “Warren Agreement”), effective as of March 1, 2022 (the “Commencement Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828022004562/0001628280-22-004562-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.